N2OFF shares surge 33.33% premarket as MitoCareX reports positive in vitro anti-inflammatory data in immune cells.

N2OFF Inc. (NASDAQ: NITO) surged 33.33% in premarket trading following the announcement of preliminary in vitro data from its subsidiary MitoCareX Bio, demonstrating that MITOLINE™-derived small-molecule candidates reduced key pro-inflammatory markers in human immune cells. The results validate mitochondrial carrier modulation as a potential therapeutic approach for inflammatory metabolic diseases, a market projected to exceed $120 billion by 2030. MitoCareX plans to advance lead candidates to pre-clinical studies, with the MITOLINE™ algorithm overcoming a critical bottleneck in mitochondrial drug discovery by enabling virtual screening of novel compounds. The news aligns with N2OFF’s strategic focus on mitochondrial-targeted therapies for oncology, autoimmune, and metabolic-inflammatory diseases, reinforcing investor confidence in its drug discovery pipeline.